Related Experiment Video

Updated: Jun 13, 2026

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

Cost-utility of molecular adsorbent recirculating system treatment in acute liver failure

Taru Kantola1, Suvi Mäklin, Anna-Maria Koivusalo

  • 1Department of Anesthesiology and Intensive Care Medicine, Surgical Hospital of Helsinki, Helsinki University Hospital, Kasarminkatu 11-13, PO Box 263, FIN-0029 HUCH, Helsinki, Finland. taru.kantola@hus.fi

World Journal of Gastroenterology
|May 12, 2010
PubMed
Abstract

Insights

Molecular adsorbent recirculating system (MARS) treatment for acute liver failure (ALF) is more cost-effective than standard care alone. MARS offers a lower average cost per quality-adjusted life year (QALY) while improving patient outcomes.

Area of Science:

  • Hepatology
  • Critical Care Medicine
  • Health Economics

Background:

  • Acute liver failure (ALF) presents significant treatment challenges.
  • Molecular adsorbent recirculating system (MARS) is an extracorporeal liver support technology.
  • Evaluating the cost-effectiveness of novel treatments is crucial for healthcare systems.

Purpose of the Study:

  • To determine the short-term cost-utility of MARS treatment in ALF patients.
  • To compare the cost per quality-adjusted life year (QALY) between MARS and standard medical treatment.
  • To assess the impact of MARS on patient survival and health-related quality of life (HRQoL).

Main Methods:

  • A retrospective controlled study involving 90 ALF patients treated with MARS and a historical control group.
  • Collection of 3-year outcome data, including liver transplantations and survival rates.
  • Determination of direct medical expenses and estimation of HRQoL using the 15D questionnaire.

Main Results:

  • Surviving ALF patients receiving MARS treatment demonstrated high HRQoL, comparable to the general Finnish population.
  • The average cost per QALY was significantly lower in the MARS group (64,732 euros) compared to controls (133,858 euros) over 3.5 years.
  • MARS treatment resulted in an incremental gain of 0.66 QALYs with an incremental cost of 10,928 euros compared to standard treatment alone.

Conclusions:

  • MARS treatment, when combined with standard medical care for ALF in an ICU setting, is more cost-effective.
  • The findings support the integration of MARS as a valuable therapeutic option for ALF.
  • MARS offers a favorable economic profile alongside clinical benefits in managing acute liver failure.

More Related Videos

Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction18:47

Surgical Procedures for a Rat Model of Partial Orthotopic Liver Transplantation with Hepatic Arterial Reconstruction

Published on: March 7, 2013

Related Concept Videos

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration01:25

Extracorporeal Removal of Drugs: Hemoperfusion and Hemofiltration

Hemoperfusion and hemofiltration are critical techniques in medical treatments to eliminate accumulated drugs, metabolites, and electrolytes from the bloodstream. These methods are particularly vital in cases of accidental poisoning and drug overdose.Hemoperfusion involves passing blood through an adsorbent material to remove unwanted substances. The main adsorbents used in hemoperfusion include activated charcoal and Amberlite resins. Activated charcoal can adsorb both polar and nonpolar...
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Continuous Renal Replacement Therapy01:30

Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...